Oncology · Clinical trials
Small-Cell Lung Cancer Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About small-cell lung cancer — and why its trials are hard
Small-cell lung cancer (SCLC) is an aggressive, high-grade neuroendocrine tumor strongly linked to smoking, notorious for rapid growth, early metastasis, and near-universal relapse after initial response. It is staged simply as limited or extensive disease. For decades, platinum-etoposide chemotherapy (with thoracic radiation and prophylactic cranial irradiation in limited stage) was the unchallenged standard, producing high response rates but short-lived remissions. The first durable advance came in 2019-2020 when adding PD-L1 inhibitors to first-line chemotherapy improved survival: atezolizumab (IMpower133) and durvalumab (CASPIAN) both extended overall survival, making chemo-immunotherapy the extensive-stage standard. Relapsed disease remains difficult: topotecan is the long-standing second-line agent, lurbinectedin gained accelerated approval in 2020 on response rate, and in 2024 tarlatamab, a first-in-class DLL3-targeting bispecific T-cell engager, was approved, validating DLL3 as an actionable target after years of failed antibody-drug conjugates. Despite these gains, absolute survival improvements are modest and SCLC remains among the most lethal thoracic cancers.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Atezolizumab + carboplatin/etoposide (Tecentriq) | 2019 | First-line extensive-stage SCLC | IMpower133 (Phase III) | Overall survival vs chemotherapy alone | Median OS 12.3 vs 10.3 months; OS HR 0.70 |
| Durvalumab + platinum/etoposide (Imfinzi) | 2020 | First-line extensive-stage SCLC | CASPIAN (Phase III) | Overall survival vs chemotherapy alone | Median OS 13.0 vs 10.3 months; OS HR 0.73 |
| Tarlatamab (Imdelltra) | 2024 | Extensive-stage SCLC after platinum-based chemotherapy | DeLLphi-301 (Phase II; accelerated approval, full approval 2025) | Objective response rate and duration of response | ORR ~40% with durable responses; first-in-class DLL3 bispecific T-cell engager |
| Lurbinectedin (Zepzelca) | 2020 | Second-line metastatic SCLC after platinum (accelerated approval) | PM1183-B-005-14 (Phase II basket) | Objective response rate | ORR ~35% overall; higher in platinum-sensitive relapse |
| Topotecan (Hycamtin) | 1996 (IV); 2007 (oral) | Second-line SCLC after first-line chemotherapy | Pivotal Phase III vs CAV / best supportive care | Response and survival/symptom control | Long-standing second-line standard; modest survival and symptom benefit |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in small-cell lung cancer development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Rovalpituzumab tesirine (Rova-T) — TAHOE and MERU (Phase III) | Failed; development discontinued | This DLL3-targeting antibody-drug conjugate showed inferior survival vs topotecan (TAHOE) and no benefit in maintenance (MERU), with notable toxicity, despite DLL3 later proving valid via tarlatamab |
| Pembrolizumab + chemotherapy — KEYNOTE-604 (Phase III) | Did not meet the survival bar for approval in first-line ES-SCLC | PFS was significant but the co-primary OS improvement did not cross the prespecified statistical boundary, so the regimen was not approved in this setting |
| Ipilimumab + chemotherapy — CA184-156 (Phase III) | Failed to improve overall survival in first-line ES-SCLC | Adding the CTLA-4 inhibitor to platinum-etoposide showed no OS benefit and added immune-related toxicity |
Choosing the right endpoint
Primary endpoints that matter in small-cell lung cancer trials
- Overall survival (OS) — The pivotal endpoint; first-line chemo-immunotherapy wins (IMpower133, CASPIAN) were defined by modest but real OS gains.
- Objective response rate (ORR) — Supported accelerated approvals for relapsed disease (lurbinectedin, tarlatamab); SCLC is highly chemo-responsive initially.
- Progression-free survival (PFS) — Commonly a co-primary; short PFS reflects SCLC's rapid relapse even after deep initial responses.
- Duration of response (DoR) — Especially important for newer agents where durability distinguishes meaningful benefit from transient shrinkage.
- Platinum-sensitive vs platinum-resistant status — The chemotherapy-free interval strongly predicts second-line response and guides relapse treatment choice.
How iNGENū runs small-cell lung cancer trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Small-Cell Lung Cancer clinical trials — FAQs
What is the current first-line standard for extensive-stage SCLC?
What is tarlatamab and why is it significant?
Why does SCLC almost always relapse?
Ready to discuss your small-cell lung cancer trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal